Email not displaying properly? View email in your browser
Hospitals Management

Advertise   |    Archives

Novo Nordisk Novo Nordisk to Invest €100 Million in Production Plants in Chartres, France

Novo Nordisk announced that it plans to invest more than 100 million euros in production facilities at its site in Chartres, France.The expansions will help Novo Nordisk meet the increasing worldwide demand for its diabetes medicines. The new facilities will be built on Novo Nordisk's existing 31,000 m2 site in Chartres, which produces a range of the company's insulin products as well as FlexPen®, the world's most widely used insulin injection device... more...

Himss AsiaPac 16
Featured Products
Bromhexine HCl
Bromhexine HCl
It is intended to support the body's mechanisms for clearing mucus from the respiratory tract. It is secretolytic, increases the production of serous mucus in the respiratory tract and makes the phlegm thinner and less viscous.This contributes to a secretomotoric effect by...


Counter Pressure Tool
Counter Pressure Tools are constructed using specially designed punching tools. Counter pressure tools, pre press the items to be punched. By doing this counter pressure tools reduces the negative influence of the cushion effect. Thus, counter pressure tools ensure accuracy and shape...


Propellant Filling Stations
Propellant Filling Stations
Centomat rotary stations are suitable for the filling and sealing of products in large series. The individual process modules may be combined to form a high-performance system or installed in an existing filling line to increase production efficiency. The pressure filler fills the propellant...


Industry Updates
MGB Biopharma’s Pre-IND Meet With US FDA Provides Clear Guidelines On Development...
MGB Biopharma, a biopharmaceutical company developing a truly novel class of anti-infectives to address the major global problem of antibiotic resistance, announced that it has held a pre-Investigational New Drug (pre-IND) meeting with the Food and Drug Administration (FDA) to discuss the regulatory strategy...
Press Releases
Aptinyx Raises $65 Million in Series A Financing to Advance Therapies for Neurological Disorders
Aptinyx Inc., a biopharmaceutical company developing novel modulators of the N-methyl-D-aspartate (NMDA) receptor for the treatment of challenging neurological disorders, today announced the completion of a $65 million Series A financing...
Events and Exhibitions
Biopharma Development & Production 2016
16th May 2016 - 19th May 2016

Grand Hyatt Shanghai,
World Cord Blood Congress Europe 2016
18th May 2016 - 19th May 2016

Business Design Centre,

Subscribe Unsubscribe Advertise Archives – a product of Ochre Media Pvt. Ltd.
Ochre Media Pvt Ltd. Media Resource Centre, 2nd Floor, Oxford Plaza, Secunderabad - 500 003, Telangana, India
Tel: +91 40 4961 4567 | Fax: +91 40 4961 4555